110 related articles for article (PubMed ID: 9032597)
1. [Growth inhibitory effects of ubenimex on leukemic cell lines resistant to chemotherapeutic agents].
Fujii H; Yosizawa K; Maruyama S; Abe F
Jpn J Antibiot; 1996 Dec; 49(12):1109-15. PubMed ID: 9032597
[TBL] [Abstract][Full Text] [Related]
2. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
3. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Tafuri A; Lemoli RM; Chen R; Gulati SC; Clarkson BD; Andreeff M
Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of bestatin on the growth of human leukemic cells.
Sakurada K; Imamura M; Kobayashi M; Tachibana N; Abe K; Tanaka M; Okabe M; Morioka M; Kasai M; Sugiura T
Acta Oncol; 1990; 29(6):799-802. PubMed ID: 2223152
[TBL] [Abstract][Full Text] [Related]
5. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
[TBL] [Abstract][Full Text] [Related]
6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy increases transgene expression in leukemic cells.
Vereecque R; Saudemont A; Depil S; Quesnel B
J Gene Med; 2003 Oct; 5(10):852-859. PubMed ID: 14533193
[TBL] [Abstract][Full Text] [Related]
8. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
9. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
10. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy.
Hu ZB; Minden MD; McCulloch EA
Leukemia; 1996 Mar; 10(3):410-6. PubMed ID: 8642855
[TBL] [Abstract][Full Text] [Related]
11. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
13. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
Nandy P; Periclou AP; Avramis VI
Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
[TBL] [Abstract][Full Text] [Related]
14. [Study on the reversing effect of tripiperaquine on human multidrug resistant leukemic cell line K562/A02].
Yang R; Yang C; Hao Y
Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):340-2. PubMed ID: 8697970
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
[TBL] [Abstract][Full Text] [Related]
17. Effect of granulocyte colony-stimulating factor on chemotherapeutic activity of cytosine arabinoside in acute leukemic cell lines.
Cha KE; Yoon SY; Lee KN
Int J Hematol; 2001 Feb; 73(2):199-205. PubMed ID: 11372732
[TBL] [Abstract][Full Text] [Related]
18. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
[TBL] [Abstract][Full Text] [Related]
19. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.
Bai H; Xu R; Cao Z; Wei D; Wang C
FEBS Lett; 2011 Jan; 585(2):402-8. PubMed ID: 21187093
[TBL] [Abstract][Full Text] [Related]
20. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
